SNMMI: Preliminary Research Suggests Dual-Targeting Radiopharmaceutical May Have Impact in Multiple Cancers

News
Article

The dual-targeted 177Lu-DOTA-FAPI-RGD reportedly reduced or stopped the growth of cancer lesions in 88.9 percent of advanced adenocarcinomas in a small cohort of patients with varied cancers including pulmonary, pancreatic and ovarian cancer, according to new research presented at the SNMMI conference.

Could an emerging radiopharmaceutical have an impact in treating advanced adenocarcinomas across multiple cancers?

In a new study, presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers explored the use of the dual-targeted radiopharmaceutical 177Lu-DOTA-FAPI-RGD for the treatment of advanced adenocarcinoma presentations in nine patients with a variety of cancers including ovarian, pancreatic, pulmonary and renal cancer.

SNMMI: Preliminary Research Suggests Dual-Targeting Radiopharmaceutical May Have Impact in Multiple Cancers

Here one can see intense uptake of 177Lu-FAPI-RGD in the majority of metastatic lesions including lung and lymph node nodules with baseline 68Ga-FAPI-RGD PET/CT imaging (left) and significant tumor size reduction in PET/CT imaging obtained after two treatment cycles with 177Lu-FAPI-RGD. (Images courtesy of SNMMI.)

The study authors found that 88.9 percent of the cohort had reductions in tumor size or cessation of tumor growth. The researchers also reported no side effects and added that many patients in the cohort experienced reduced pain as well as improved appetite and quality of life.

“This first-in-human dosimetry trial of 177Lu-DOTA-FAPI-RGD highlights its potential applicability across a broad spectrum of oncological diseases. The dual-targeting radioligand, 177Lu-DOTA-FAPI-RGD, exhibited an acceptable safety profile, significant tumor uptake and retention, and a promising therapeutic response,” noted lead study author Jialin Xiang, a PhD student at Peking Union Medical College Hospital in Beijing, China, and colleagues.

(Editor’s note: For additional coverage of news and research from the SNMMI conference, click here.)

The researchers emphasized that the significant uptake of 177Lu-DOTA-FAPI-RGD and its long retention facilitated high targeted dosing, citing 4.3 Gy/GBq for lung metastases as an example.

“The beauty of this drug is that it stays in tumors for days, allowing prolonged damage to cancer cells. It offers real hope for patients with advanced cancers who have exhausted other treatment options,” added Xiang.

(Editor’s note: For related content, see “Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?,” “What SPECT/CT May Reveal About Early Treatment Response for Pluvicto in Patients with mCRPC” and “New Study Shows Impact of Tau-Positive PET in Risk Stratification for Dementia and Alzheimer’s Disease.”)

Reference

  1. Xiang J, Wang R, Wang J, Peng X, Wang Y, Zhu Z. Preliminary safety, biodistribution, and dosimetry of fibroblast activation protein and integrin avB3 dual targeting radioligand 177Lu-DOTA-FAPI-RGD: first-in-human results. Presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, June 21-24, 2025. Available at: https://jnm.snmjournals.org/content/66/supplement_1/251663 .
Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Related Content
© 2025 MJH Life Sciences

All rights reserved.